Aarti Drugs Limited (BOM: 524348)

Market Cap	43.03B
Revenue (ttm)	23.80B
Net Income (ttm)	1.52B
Shares Out	91.94M
EPS (ttm)	16.62
PE Ratio	28.16
Forward PE	27.37
Dividend	1.00 (0.21%)
Ex-Dividend Date	n/a

Volume	6,199
Open	467.00
Previous Close	467.20
Day's Range	453.60 - 471.95
52-Week Range	430.00 - 634.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 24, 2025

About Aarti Drugs

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, ti...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1984
• Employees: 1,064
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524348

Financial Performance

In 2023, Aarti Drugs's revenue was 25.29 billion, a decrease of -6.90% compared to the previous year's 27.16 billion. Earnings were 1.71 billion, an increase of 3.07%.